U.S. Residential REITs Stock News

NYSE:AHR
NYSE:AHRHealth Care REITs

US REIT Stocks Back In Focus As Lower Yields Lift Healthcare Property Names

Softer US jobs data and easing Treasury yields have quickly shifted attention back to interest rate sensitive areas of the market. That includes US REIT stocks that can feel every move in borrowing costs and inflation expectations. For investors who do not want to wait on the sidelines, this backdrop may create chances to reassess income focused real estate exposure. This article reveals three REIT stocks from the screener that appear positively exposed to the latest macro signals, and...
NasdaqCM:NNE
NasdaqCM:NNEElectrical

Constellation Energy Stock And 2 Nuclear Picks for Reliable Carbon Free Power

Oil price volatility linked to Middle East shipping routes keeps energy security at the center of market conversations. That backdrop puts nuclear energy stocks in sharper focus for investors who want power sources that are not tied to daily oil headlines. The Nuclear Energy Stocks screener filters this broad theme into a focused watchlist. In this article you will see three stand out stocks worth a closer look. The three nuclear energy stocks in this article are just a starting sample, and...
NasdaqGM:SHLS
NasdaqGM:SHLSElectrical

Shoals Technologies Group (SHLS) Reaffirms Guidance As TerraFlow Deal Tests Its Valuation

Shoals Technologies Group (SHLS) has just combined a fresh earnings update with reaffirmed 2026 revenue guidance and a new TerraFlow Energy agreement, giving investors new information on growth, margins and future project visibility. See our latest analysis for Shoals Technologies Group. The recent guidance reaffirmation and TerraFlow Energy MOU come after a mixed share price stretch for Shoals Technologies Group, with a 1-day share price return of 3.84% contrasting with a 30-day share price...
NYSE:LEA
NYSE:LEAAuto Components

Lear (LEA) Raised Full Year Guidance, Is It Still Below Fair Value?

Lear (LEA) drew fresh attention after raising its full-year 2026 revenue guidance to approximately US$23.8b and reporting second-quarter sales of US$6,209.4m with net income of US$192.8m. See our latest analysis for Lear. Lear's recent news around higher full-year revenue guidance and stronger second quarter earnings has come as the share price has been under pressure. The 30 day share price return is down 9.8% and the 90 day share price return is down 9.9%, while the 1 year total shareholder...
NasdaqGS:TDUP
NasdaqGS:TDUPSpecialty Retail

ThredUp (TDUP) Following New Guidance Still Looks Undervalued On Some Views

Why ThredUp Stock Is Back In Focus After New Guidance ThredUp (TDUP) is drawing fresh attention after releasing second quarter 2026 results, alongside new revenue guidance for the next two quarters and the full year, giving investors updated visibility into the resale platform’s growth profile. See our latest analysis for ThredUp. The updated guidance has arrived after a difficult stretch for ThredUp shareholders, with the stock moving to $3.21 and recording a 7-day share price return down...
NYSE:PUMP
NYSE:PUMPEnergy Services

Oil Stocks To Watch As Strait Of Hormuz Disruption Lifts Energy Prices

Energy stocks are back in the spotlight as shipping traffic through the Strait of Hormuz is disrupted, oil prices react, and headlines move markets day by day. When trade routes shift and risk premiums ripple through the system, certain oil and gas producers can see their prospects change quickly. This article walks through 3 stocks from our Energy Sector Stocks screener that appear positively exposed to the current news story. The three stocks covered below are just a starting sample from...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

What Incyte (INCY)'s Expanded Opzelura EU Approval Means For Shareholders

In the past week, Incyte reported that the European Commission approved Opzelura (ruxolitinib) cream for moderate atopic dermatitis in adults who do not respond adequately to or cannot use standard topical therapies, expanding the drug’s European label beyond non-segmental vitiligo. This decision, backed by strong Phase 3 data showing rapid itch relief and durable skin clearance with a favorable safety profile, coincided with Incyte posting higher quarterly revenue and net income and raising...
NYSE:SITE
NYSE:SITETrade Distributors

SiteOne’s Buybacks And Acquisition Push Could Be A Game Changer For SiteOne Landscape Supply (SITE)

In late July 2026, SiteOne Landscape Supply reported second-quarter sales of US$1,530.7 million and net income of US$139.3 million, alongside confirmation that it had repurchased 897,778 shares for US$103.76 million under its ongoing buyback program. Management also highlighted an active acquisition pipeline, with two deals already completed in 2026 adding about US$110 million in trailing sales, signalling continued emphasis on growth through consolidation in a fragmented landscape supply...
NYSE:CBT
NYSE:CBTChemicals

Can Cabot (CBT) Justify Its Valuation Following Weaker Earnings And A CEO Transition?

Cabot (CBT) has drawn investor attention after third quarter earnings on 3 August 2026 showed sharply lower net income and earnings per share, along with previously announced leadership changes at the top of the company. See our latest analysis for Cabot. Cabot's recent earnings miss and upcoming CEO transition sit against a share price that has climbed 30.68% year to date, with a 5 year total shareholder return of 77.28%. This suggests longer term momentum has been stronger than the shorter...
NYSE:CPRI
NYSE:CPRILuxury

Capri Holdings (CPRI) Is Down 6.5% After Raising EPS Guidance Despite Kors Inventory Delays

Capri Holdings Limited recently reported past first-quarter 2027 results, with sales easing to US$769 million while net income rose to US$69 million, and issued new second-quarter and full-year guidance outlining revenue pressures from Michael Kors inventory delays, softer EMEA demand and foreign exchange headwinds. Alongside this, Capri filed a US$41.30 million shelf registration for 2,500,000 common shares tied to an employee share offering, adding a capital structure element to investors’...
NasdaqGS:GH
NasdaqGS:GHHealthcare

Guardant Health (GH) Is Up 6.1% After Raising 2026 Revenue Outlook And Filing Shelf Registration - Has The Bull Case Changed?

In late July 2026, Guardant Health reported second-quarter 2026 results showing sales of US$334.98 million and a net loss of US$120.14 million, alongside higher full-year revenue guidance of US$1.34–1.36 billion. The company also filed an omnibus shelf registration covering multiple securities and highlighted surging Shield screening volumes supported by new UnitedHealth coverage and recent FDA approvals. Next, we’ll examine how Guardant Health’s increased 2026 revenue guidance, underpinned...
NYSE:CPT
NYSE:CPTResidential REITs

Camden’s California Exit and Capital Shifts Might Change The Case For Investing In Camden Property Trust (CPT)

In recent weeks, Camden Property Trust completed the US$1.63 billion sale of its California portfolio, filed an US$802.87 million shelf registration for 7,250,000 common shares tied to an ESOP, updated 2026 earnings guidance, and finished a US$302.20 million share repurchase program covering 4,062,166 shares. These moves mark a significant repositioning of the portfolio toward newer Sunbelt assets while simultaneously shifting capital between buybacks and employee ownership, all against a...
NYSE:OC
NYSE:OCBuilding

What Is Behind Owens Corning (OC) Shares Climbing Today?

How Owens Corning’s Latest Earnings Shape the Story for Investors Owens Corning (OC) has attracted fresh attention after its second quarter 2026 earnings update, which paired broadly steady sales with softer profits, ongoing buybacks, and clearer guidance on upcoming segment trends and costs. See our latest analysis for Owens Corning. The earnings release and the appointment of a new CFO have come alongside brisk share price momentum for Owens Corning, with a 31.1% 90-day share price return...
NasdaqGS:GERN
NasdaqGS:GERNBiotechs

Geron (GERN) Is Up 15.6% After Raising 2026 RYTELO Revenue Guidance And Filing New ESOP Shares

In August 2026, Geron Corporation reported second-quarter 2026 results showing revenue of US$57.48 million versus US$49.04 million a year earlier, alongside a six-month net loss of US$20.32 million, and issued 2026 guidance projecting RYTELO net product revenue between US$220 million and US$240 million. The company also filed a US$6.03 million shelf registration for 4,500,000 common shares tied to an ESOP, highlighting ongoing use of equity-based compensation. We’ll now examine how Geron’s...
NasdaqGS:PCRX
NasdaqGS:PCRXPharmaceuticals

Pacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data

Pacira BioSciences recently reported that its investigational gene therapy PCRX-201 for knee osteoarthritis showed positive two-year Phase 1 results, with a single intra-articular dose appearing well tolerated and associated with improvements in pain, stiffness, and function, and incorporated glucocorticoid pretreatment into its ongoing Phase 2 ASCEND study following favorable safety findings. By pairing encouraging long-term clinical data with a successful transition to scalable U.S.-based...
NYSE:NBHC
NYSE:NBHCBanks

National Bank Holdings (NBHC) Affirms Dividend, Is The Valuation Discount Enough?

Dividend affirmation puts National Bank Holdings in focus National Bank Holdings (NBHC) has drawn fresh attention after its board declared a quarterly cash dividend of $0.32 per share, payable on September 15, 2026 to shareholders of record on August 28. See our latest analysis for National Bank Holdings. Alongside the confirmed dividend, National Bank Holdings shares trade at $42.62, with the 1 month share price return down 3.86% while the year to date share price return is up 12.45% and the...
NYSE:PRLB
NYSE:PRLBMachinery

Proto Labs (PRLB) Lifts Outlook As Fair Value Looks Fully Valued

Why Proto Labs Stock Is Back In Focus After Its Latest Earnings Proto Labs (PRLB) is drawing renewed investor attention after its second quarter 2026 earnings, full year outlook update, and an employee stock offering were all announced on 31 July 2026. See our latest analysis for Proto Labs. The strong second quarter update and raised 2026 revenue growth outlook have arrived alongside a sharp shift in sentiment. Proto Labs has posted a 19.5% 1 month share price return and a 92.28% 1 year...